Archive for the ‘research’ Category

Penile Cancer After a Tick Bite: A Possible Association

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323426/

 2021; 9: 2050313X211036779.
Published online 2021 Jul 28. doi: 10.1177/2050313X211036779
PMCID: PMC8323426
PMID: 34377488

Penile cancer after a tick bite: A possible association

Ognen Ivanovski,1 Skender Saidi,1 Bashkim Shabani,1 Slobodan Gurmeshevski,1 Risto Pejkov,1 Selim Komina,2 and Aleksandra Gavrilovska-Brazanov3
Author information Article notes Copyright and License information Disclaimer

Abstract

Penile cancer is a rare cancer in Western countries, but is more common in parts of the developing world. Usually, it is associated with older uncircumcised men who have a long-term phymotic preputium. Here, we report a case of penile cancer in a circumcised patient, occurring 3 months after a tick bite on the head of the penis. To the best of our knowledge, this is the first report that suggests a possible association between Lyme disease and occurrence of “de novo” penile cancer. Further studies are needed to confirm this hypothesis.

_______________

**Comment**

Other research has implicated tick-borne illness with cancer, as well as the COVID shots.

And these studies will never happen because Fauci, the highest paid government employee who owns numerous patents, is the gatekeeper of immunosuppression diseases. What’s important about this is that if immunosuppression diseases actually exist, vaccines become obsolete. Mafia overlord, Fauci can not allow the truth to come out because our government owns over 50 patents on vaccines, and NIH owns half of the Moderna COVID shot.  There’s simply too much at stake.

Fauci, head of NIAID for 7 presidencies, is also the controller of the purse strings for government research grants and researchers know they must tout the accepted narrative if they want funding. He would rather fund lucrative, but horrifically grizzly experiments on children and puppies – and of course big cash cows like mRNA products and “vaccines,” that our corrupt public health agencies own patents on and receive secret payments from.  It’s a win-win for government and Big Pharma while the public suffers in silence.

For more:

Ticks manage to get everywhere.

Category:

Lyme, research, Ticks, Transmission

Low Dose Naltrexone for Chronic Pain

https://www.paintreatmentdirectory.com/posts/low-dose-naltrexone-for-chronic-pain

Low Dose Naltrexone for Chronic Pain

Low Dose Naltrexone for Chronic Pain

By: Chris Graf

11/7/22

Low doses of a drug that is commonly prescribed to recovering alcoholics and narcotic addicts is being used to help chronic pain sufferers find relief from a variety of pain conditions including fibromyalgia, inflammatory bowel, Crohn’s disease, and complex regional pain syndrome.  The drug is called naltrexone.

What is naltrexone?

Naltrexone is a prescription medication used to suppress narcotic and alcohol cravings in recovering addicts. Naltrexone is used as just one part of an addict’s overall treatment plan. It is prescribed only after a person is no longer dependent on drugs or alcohol.

How does Naltrexone work?

Naltrexone blocks the euphoric sensations associated with narcotic and alcohol use. It is non-addictive and produces no narcotic-like effects.

Researchers believe that naltrexone also modulates the release of inflammatory chemicals in the central nervous system. The drug temporarily binds to and blocks the Mu opioid receptors (MORs) which are central to pain control. When these receptors are blocked, the body responds by producing more pain-relieving endorphins.

Dosage of naltrexone for addiction vs for pain relief

When used for the management of addiction, the typical daily dosage of naltrexone is 50–100 mg per day. For chronic pain relief, the dosage is typically less than 8 mg per day. Patients may start off with a dose as low as .01 mg. A more typical starting dose is 1.5 mg. On average, dosages of low-dose naltrexone (LDN) are approximately 1/10th of the typical addiction treatment dosage.

Prescriptions for LDN can be filled by compounding pharmacies that grind up the higher dose tablet into ultra-low doses.

Are there side effects of naltrexone?

Common side effects of naltrexone when used for addiction management include nausea, fatigue, and loss of appetite. While most side effects are mild, serious side effects are possible. The Mayo Clinic provides a comprehensive list of all possible side effects. Side effects are less likely to occur in patients taking low doses of the drug.

A 2014 review found that the use of LDN for pain relief was “well tolerated” by patients and that there was “low reported incidence of adverse side effects.”

Research on low-dose naltrexone for pain relief

  • Results of a review conducted in 2014 indicated that “Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn’s disease, multiple sclerosis, and complex regional pain syndrome.” The review found Crohn’s disease to be the condition with the most scientific support when it comes to the efficacy of LDN for pain relief.
  •  A 2018 review found that “Clinical reports of LDN have demonstrated possible benefits in diseases such as fibromyalgia, Crohn’s disease, multiple sclerosis, complex-regional pain syndrome, Hailey-Hailey disease, and cancer.”
  • According to a 2020 review, “Low-dose naltrexone (LDN) has shown promise to reduce symptoms related to chronic pain conditions such as fibromyalgia, inflammatory bowel conditions, and multiple sclerosis.”
  • A systematic review conducted by the University of Michigan School of Dentistry concluded that “Low-dose naltrexone provides an alternative in medical management of chronic pain disorders as a novel anti-inflammatory and immunomodulator. It can offer additional management options, as orofacial pain conditions share characteristics with other chronic pain disorders.” Authors of the study consider the drug “a good option for patients with orofacial and chronic pain, without the risk of addiction.”

What pain management specialists say about LDN

According to an article published by Weill Cornell Medicine in September 2020, their pain management specialists have had success treating chronic pain patients with low-dose naltrexone. When interviewed, Dr. Neel Mehta, said, “Generally, my patients report pain relief greater than 50 percent, that they’re sleeping better, or can return to work. And some patients end up responding well to doses as low as 0.1 for reasons we don’t yet completely understand. Patients are experiencing good results with low harm in these early studies.”

In an article published by NPR, Dr. Bruce Vroorman, an associate professor at Dartmouth’s Geisel School of Medicine and the author of the above-mentioned 2018 review, was interviewed. According to the article, “Vrooman says that when it comes to treating some patients with complex chronic pain, low-dose naltrexone appears to be more effective and well-tolerated than the big-name opioids that dominated pain management for decades.” He said that LDN is a “game changer” for some chronic pain patients.

In an interview with Michigan News, orofacial pain specialist Elizabeth Hatfield discussed the use of LDN. She said, “We found a reduction in pain intensity and improvement in quality of life, and a reduction in opioid use for patients with chronic pain.” She went on to say that it is best used on centralized pain disorders including fibromyalgia, complex regional pain syndrome, and TMJ.

Low-dose naltrexone may be a possible treatment for long COVID

According to a recent article published by Reuters, Dr. Jack Lambert, an infectious disease expert at University College Dublin School of Medicine, ran a pilot study on the use of LDN for long COVID. Lambert has reported previous success in using LDN to treat pain and fatigue associated with chronic Lyme disease.

After being treated with LDN for two months, the 38 pilot study participants reported improvement in energy, pain, concentration, insomnia and overall recovery from COVID-19.

Lambert is preparing to run a larger trial to confirm the results. He believes it is possible that LDN may work to repair the damage done to the body by the virus. 

Conclusion

Low-dose naltrexone appears to be safer and more effective for chronic pain than widely used opioids. It might be worth a try if you’re in chronic pain and want to avoid, reduce or eliminate the use of opioids. It’s important to find a knowledgeable healthcare provider who can guide you in terms of dosages and how to taper off of opioids safely.

Other options that involve oral administration of a substance in order to avoid, reduce or eliminate the use of opioids while safely improving pain relief include marijuana, CBD, kratom, an anti-inflammatory diet, nutritional supplements including vitamin D and magnesium.

Find an Alternative Pain Treatment Provider Near You

Find Natural Pain Relief Products

Christine Graf is a freelance writer who lives in Ballston Lake, New York. She is a regular contributor to several publications and has written extensively about health, mental health, and entrepreneurship.  

For more:

Category:

Lyme, Pain Management, research, Treatment, Viruses

COVID Spreads Through Floors & Walls. COVID, Masks, & Shots Cause Low Oxygen & Blood Clotting So Why Are People Still Wearing Masks?

https://wwwnc.cdc.gov/eid/article/28/12/22-0666_article

Volume 28, Number 12—December 2022

Probable Aerosol Transmission of SARS-CoV-2 through Floors and Walls of Quarantine Hotel, Taiwan, 2021

Hsin-Yi Wei, Cheng-Ping Chang, Ming-Tsan Liu, Jung-Jung Mu, Yu-Ju Lin, Yu-Tung Dai, and Chia-ping Su
Author affiliations: Taiwan Centers for Disease Control, Ministry of Health and Welfare, Taipei, Taiwan (H.-Y. Wei, M.-T. Liu, J.-J. Mu, Y.-J. Lin, C.-p. Su); Chang Jung Christian University, Tainan, Taiwan (C.-P. Chang, Y.-T. Dai)

Abstract

We investigated a cluster of SARS-CoV-2 infections in a quarantine hotel in Taiwan in December 2021. The cluster involved 3 case patients who lived in nonadjacent rooms on different floors. They had no direct contact during their stay. By direct exploration of the space above the room ceilings, we found residual tunnels, wall defects, and truncated pipes between their rooms. We conducted a simplified tracer-gas experiment to assess the interconnection between rooms. Aerosol transmission through structural defects in floors and walls in this poorly ventilated hotel was the most likely route of virus transmission. This event demonstrates the high transmissibility of Omicron variants, even across rooms and floors, through structural defects. Our findings emphasize the importance of ventilation and integrity of building structure in quarantine facilities.

_________________

https://www.theepochtimes.com/health/why-spike-protein-causes-abnormal-blood-clots-200-symptoms

Why Spike Protein Causes Abnormal, Foot-Long Blood Clots, 200 Symptoms

In this two-part paper, we aim to give an overview on COVID-19 related abnormal blood clots, how they form, how to detect them early, and how they’re being treated
Dr. Yuhong Dong and Dr. Jordan Vaughn
 
Nov 5 2022
 
Excerpts:
 
Physicians have summarized a list of unusual clinical observations of COVID-19 including but not limited to severely hypoxic (low oxygen) patients despite relatively normal lung compliance upon examination, thrombotic complications, and consistent autopsy findings of blood clots (thrombi) in the microcirculation of the lung.

Spike Proteins trigger the clotting cascade

Spike Protein dysregulates RAAS, and competitively inhibits the bindings of antithrombin and heparin cofactor II, worsening the clotting

Spike Proteins directly disrupt the clot dissolving mechanism

Spike Proteins form amyloid-Like substance

The experimental COVID gene-therapy injections contain the spike protein and have caused clotting

Since blood vessels are in all our organs, clotting in the vessels would explain the wide range of symptoms experienced

(See link for article)

___________________

**Comment**

Not to be Captain Obvious, but hopefully the knowledge that COVID can pass through floors and walls and consists of a spike protein that causes low oxygen and breathlessness, clearly shows the worthlessness and indeed danger of mask usage since masks also cause hypoxia.

An eleven month old just DIED from mask asphyxiation in Taiwan.

Don’t get me wrong. There are times to wear a mask for short periods of time, like when you are restoring furniture and kicking up saw dust when using a sander, or when you are dealing with scary chemicals that could damage your lungs. Please, by all means, wear a mask when you are participating in such endeavors!

However, if you still are under the false belief that a mask can stop a virus smaller than the pores in the mask, you are following pseudoscience and propaganda. Throw those suckers away and breathe. Deeply.

What the study should have emphasized is the fact you can not stop viruses. Period. They simply must run their course through a population. What you can productively do is make yourself a tougher target by taking appropriate action for creating a healthy immune system. You can also be prepared with safe, effective, cheap treatments to take early on, should you become ill.

Corrupt public health has made this quite difficult if not impossible by censoring, banning, and maligning anything that competes with their lucrative, vested interests with Big Pharma. These corrupt public health agencies have successfully frightened the public into taking an expensive, experimental, ineffective, and a dangerous gene therapy shot they own half the patent on.

For more on masks:

For more on how to protect against and treat COVID:

Live free and breathe deeply.

Category:

Activism, research, Transmission, Treatment, vaccines

Meningoencephalitis Due to Borrelia Miyamotoi

https://danielcameronmd.com/meningoencephalitis-borrelia-miyamotoi/

Meningoencephalitis due to Borrelia miyamotoi

Meningoencephalitis-Borrelia-miyamotoi
In their case report, Gandhi and colleagues, describe an immunocompetent patient who developed acute-onset, progressive encephalopathy due to an infection with Borrelia miyamotoi.

By Dr. Daniel Cameron

A 73-year-old man was admitted to the hospital with a 16-day history of confusion and intermittent headaches. He was an avid gardener and reportedly had tick bites in the past but none that he noticed in the weeks prior to his symptoms.

Initially, he developed “right-sided facial droop and associated numbness, confusion, and word-finding difficulties,” the authors write in the article “Borrelia miyamotoi Meningoencephalitis in an Immunocompetent Patient.”¹

His symptoms, which had improved, were attributed to a mini-stroke.

However, “Over the next 2 weeks, he continued to feel numbness in his right face and developed worsening confusion, intermittent headaches, and excessive fatigue; he was afebrile throughout this time.”¹

The patient tested positive for Lyme disease by EIA but negative by Western blot.

He was “empirically treated with intravenous ceftriaxone for treatment of presumed Lyme meningoencephalitis, and his mental status rapidly improved,” the authors write.

READ MORE: What is Borrelia miyamotoi?

When repeat testing for Lyme disease was negative by Western blot, clinicians considered another tick-borne infection – Borrelia miyamotoi.

The man tested positive for B. miyamotoi and made a “nearly full neurological recovery with only residual intermittent right facial numbness” after anti-Borrelia antibiotic treatment.

The authors conclude:

  • “Our case therefore highlights the need to include B. miyamotoi disease in the differential diagnosis for any patient who presents with acute onset, progressive encephalopathy with culture-negative CSF in B. miyamotoi–endemic regions, not just those who are immunocompromised.”
  • “Our case highlights the importance of considering B. miyamotoi in clinically suspicious cases of meningoencephalitis, including when B. burgdorferi EIA results are positive but the WB is negative.”
Related Articles:

Could Borrelia miyamotoi infections explain persistent symptoms in Lyme disease patients?
Blood smear not reliable in diagnosing Borrelia miyamotoi disease
Doctors face challenges in diagnosing Borrelia miyamotoi

References:
  1. Gandhi S, Narasimhan S, Workineh A, Mamula M, Yoon J, Krause PJ, Farhadian SF. Borrelia miyamotoi Meningoencephalitis in an Immunocompetent Patient. Open Forum Infect Dis. 2022 Jun 13;9(7):ofac295. doi: 10.1093/ofid/ofac295. PMID: 35873293; PMCID: PMC9301576.

For more:

Category:

Borrelia Miyamotoi (Relapsing Fever Group), research, Ticks

Study: IFR Estimates in Non-elderly Populations Lower Than Previous Calculations & Risk of Dying From COVID Was Always “Miniscule”Regardless of Age

https://www.medrxiv.org/content/10.1101/2022.10.11.22280963v1

Age-stratified infection fatality rate of COVID-19 in the non-elderly informed from pre-vaccination national seroprevalence studies

Angelo Maria Pezzullo, Cathrine Axfors, Despina G. Contopoulos-Ioannidis, Alexandre Apostolatos, John P.A. Ioannidis
doi: https://doi.org/10.1101/2022.10.11.22280963

This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

ABSTRACT

The infection fatality rate (IFR) of COVID-19 among non-elderly people in the absence of vaccination or prior infection is important to estimate accurately, since 94% of the global population is younger than 70 years and 86% is younger than 60 years. In systematic searches in SeroTracker and PubMed (protocol: https://osf.io/xvupr), we identified 40 eligible national seroprevalence studies covering 38 countries with pre-vaccination seroprevalence data. For 29 countries (24 high-income, 5 others), publicly available age-stratified COVID-19 death data and age-stratified seroprevalence information were available and were included in the primary analysis.

  • The IFRs had a median of 0.035% (interquartile range (IQR) 0.013 – 0.056%) for the 0-59 years old population
  • 0.095% (IQR 0.036 – 0.125%,) for the 0-69 years old
  • The median IFR was:
    • 0.0003% at 0-19 years
    • 0.003% at 20-29 years
    • 0.011% at 30-39 years
    • 0.035% at 40-49 years
    • 0.129% at 50-59 years
    • 0.501% at 60-69 years

Including data from another 9 countries with imputed age distribution of COVID-19 deaths yielded median IFR of 0.025-0.032% for 0-59 years and 0.063-0.082% for 0-69 years. Meta-regression analyses also suggested global IFR of 0.03% and 0.07%, respectively in these age groups. The current analysis suggests a much lower pre-vaccination IFR in non-elderly populations than previously suggested. Large differences did exist between countries and may reflect differences in comorbidities and other factors. These estimates provide a baseline from which to fathom further IFR declines with the widespread use of vaccination, prior infections, and evolution of new variants.

Highlights *Across 31 systematically identified national seroprevalence studies in the pre-vaccination era, the median infection fatality rate of COVID-19 was estimated to be 0.035% for people aged 0-59 years people and 0.095% for those aged 0-69 years.

*The median IFR was 0.0003% at 0-19 years, 0.003% at 20-29 years, 0.011% at 30-39 years, 0.035% at 40-49 years, 0.129% at 50-59 years, and 0.501% at 60-69 years.

*At a global level, pre-vaccination IFR may have been as low as 0.03% and 0.07% for 0-59 and 0-69 year old people, respectively.

*These IFR estimates in non-elderly populations are lower than previous calculations had suggested.

For more:  https://media.mercola.com/ImageServer/Public/2022/October/PDF/mortality-risk-covid-pdf.pdf  Excerpt:

  • Polls taken in 2020 and 2021 revealed Americans were wildly confused and misinformed about their true risk of dying from COVID
  • Based on a new preprint analysis by professor John Ioannidis, there’s no reason for anyone to live in fear anymore, regardless of your age, as your risk of dying from COVID is — and always was — minuscule across the board
  • Before the COVID jabs were rolled out:
    • if you were 19 or younger, your risk of dying of COVID was 0.0003%; only 3 per 1 million infected with COVID at this age ended up dying
    • Between ages 60 and 69, the infection fatality rate was 0.501%, i.e., 1 out of 200 infected died
  • Emerging evidence suggests the shots are causing immune deficiency in some people, thereby actually raising their risk of dying from SARS-CoV-2 infection, even with the now-milder strains
  • The real-world risk of dying from COVID-19 based on published data from the Irish census bureau and the central statistics office for 2020 and 2021 is as follows:
    • for people under 70, the death rate was 0.014%
    • under 50 years of age, it was 0.002%, which equates to a 1 in 50,000 risk, or about the same as dying from fire or smoke inhalation
    • under 25 years of age, the mortality rate was 0.00018%, or 1 in 500,000 risk of dying from COVID

Despite this reality which was stated early on by those who dared to defy the accepted narrative, Harvard has mandated the new COVID booster, threatening to hold enrollment if students don’t comply.  Many places still require masking which has been proven to not only be dangerous, but utterly futile as a new study shows viral aerosols likely spread through the floors and walls.  A porous mask doesn’t stand a chance.

Category:

Activism, research, vaccines, Viruses